NCT01695707

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Many patients with eczema (atopic dermatitis) have an inherent defect in their skin barrier as demonstrated by high water loss. In laboratory conditions, studies have shown that pioglitazone restores the skin barrier function in skin from eczema patients. The purpose of this study is to determine if taking pioglitazone improves the skin barrier function in people with eczema.

Detailed description

Enrolled patients will be randomized to either placebo or pioglitazone. Each randomized subject will have a skin biopsy and skin irritancy assay performed prior to treatment and at the end of 12 weeks of treatment. Noninvasive barrier measurements including transepidermal water loss will be recorded at all study visits.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Pioglitazone	see Arm Description
DRUG	Placebo (for pioglitazone)	see Arm Description

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-01-01
• Completion: 2014-06-01
• First posted: 2012-09-28
• Last updated: 2014-12-02

Locations

1 site across 1 country: United States